Trikafta Kit
Product Images NDC 51167-106

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Trikafta (NDC 51167-106). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Vertex Pharmaceuticals Incorporated, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Trikafta 01)

Chemical structure of Elexacaftor, one of the active ingredients in Trikafta, a human prescription drug kit by Vertex Pharmaceuticals Incorporated. The diagram shows the detailed molecular arrangement and bonds within the Elexacaftor molecule.*

FDA Label Image

Chemical Structure (Trikafta 02)

Chemical structure diagram of Elexacaftor, one of the active ingredients in Trikafta (Elexacaftor, Tezacaftor, and Ivacaftor). The diagram shows the molecular arrangement with fluorine, oxygen, nitrogen, and other atoms represented.*

FDA Label Image

Chemical Structure (Trikafta 03)

Chemical structure of Elexacaftor, one of the active ingredients in the prescription drug Trikafta. The diagram shows the molecular arrangement including functional groups and ring structures present in Elexacaftor.*

FDA Label Image

Figure 1 (Trikafta 04)

A line graph depicting the LS mean change in ppFEV1 over multiple visits from Baseline to Week 24. It compares two groups: Placebo, shown as a dashed line with open circles, and ELX/TEZ/IVA (Elexacaftor, Tezacaftor, Ivacaftor), shown as a solid line with filled triangles. The ELX/TEZ/IVA group shows a marked increase in ppFEV1 by Day 15, which remains stable through Week 24, while the Placebo group shows minimal change.*

FDA Label Image

Principal Display Panel (Kit Carton)

Trikafta kit packaging label showing the product name, active ingredients (elexacaftor 100 mg, tezacaftor 50 mg, ivacaftor 75 mg, and ivacaftor 150 mg tablets), and quantity (84 tablets). The label includes manufacturer information (Vertex Pharmaceuticals Incorporated) and visual branding elements. Dosage instructions and storage information are also partially visible.*

FDA Label Image

Principal Display Panel (Kit Carton)

The packaging label for Trikafta tablets includes the proprietary name and the active ingredients: elexacaftor, tezacaftor, and ivacaftor. It specifies tablet strengths of 50 mg, 25 mg, and 37.5 mg for elexacaftor, tezacaftor, and ivacaftor, and 75 mg for ivacaftor alone. The label shows that the kit contains 84 tablets, divided into 4 wallets with specified tablet quantities. The labeler is Vertex Pharmaceuticals Incorporated. Instructions and dosing reminders are also printed on the label.*

FDA Label Image

Principal Display Panel (Kit Carton)

Trikafta 80 mg/40 mg/60 mg oral granules co-packaged with Ivacaftor 59.5 mg oral granules kit packaging label. The label shows dosing instructions with morning and evening packets, NDC 51167-445-01, and includes the manufacturer Vertex Pharmaceuticals Incorporated. It indicates 56 packets per carton and storage instructions.*

FDA Label Image

Principal Display Panel (Kit Carton)

Trikafta oral granules kit packaging label by Vertex Pharmaceuticals Incorporated. The label shows the active ingredients elexacaftor, tezacaftor, and ivacaftor with strengths of 100 mg, 50 mg, and 75 mg respectively, co-packaged with ivacaftor 75 mg oral granules. The carton contains 56 packets organized into 4 individual wallets with 14 packets each. It includes instructions for pharmacist dispensing and simple graphics illustrating morning and evening dosing 12 hours apart.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.